Ladi-Seyedian SS, et al. - An inquiry was set up in order to inspect the long-term efficacy and success rate of intravesical electromotive botulinum toxin type A (BoNTA) “Dysport” administration in myelomeningocele (MMC) patients who had urinary incontinence due to neuropathic detrusor overactivity (NDO). electromotive drug administration (EMDA)/BoNTA was illustrated as being a feasible, safe, reproducible, cost-effective, long-lasting and pain-free method as an outpatient's basis with long-term duration of effects without anesthesia or cystoscopy procedure. Significant improvement was yielded in urinary incontinence and UDS parameters through this novel delivery system, in patients with refractory NDO.